| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50090-7305-00 | 50090-7305 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 14, 2024 | In Use | |
| 50090-7481-00 | 50090-7481 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Dec 20, 2024 | In Use | ||
| 50090-7688-00 | 50090-7688 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 9, 2025 | In Use | |
| 50242-0063-01 | 50242-0063 | Erlotinib Hydrochloride | Tarceva | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2005 | In Use | |
| 50242-0079-08 | 50242-0079 | Inavolisib | Itovebi | 9.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Oral | Oct 14, 2024 | In Use | |
| 50268-0407-15 | 50268-0407 | Hydrocortisone | HYDROCORTISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 31, 2023 | In Use | |
| 50419-0385-01 | 50419-0385 | Copanlisib | Aliqopa | 15.0 mg/mL | Chemotherapy | Enzyme Inhibitor | PI3K | Intravenous | Sep 14, 2017 | In Use | |
| 50742-0366-30 | 50742-0366 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 27, 2023 | In Use | |
| 50242-0094-47 | 50242-0094 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug 15, 2019 | In Use | |
| 50742-0387-01 | 50742-0387 | Estrogens, conjugated | Estrogens, conjugated | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 16, 2025 | In Use | ||
| 50742-0492-01 | 50742-0492 | Carmustine | CARMUSTINE | Chemotherapy | Alkylating Agent | Nitrosourea | Jun 25, 2022 | In Use | |||
| 70954-0054-10 | 70954-0054 | Hydrocortisone | Hydrocortisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 5, 2025 | In Use | |
| 50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 22, 2023 | In Use | |
| 51013-0190-09 | 51013-0190 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 29, 2018 | In Use | |
| 51407-0702-02 | 51407-0702 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Jun 11, 2025 | In Use | |
| 43598-0342-11 | 43598-0342 | Pralatrexate | Pralatrexate | 20.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Nov 1, 2025 | In Use | |
| 63629-1579-08 | 63629-1579 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 5, 2009 | In Use | |
| 68791-0104-04 | 68791-0104 | Prednisolone Sodium Phosphate | Pediapred | 5.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 7, 2018 | In Use | |
| 00409-0367-01 | 00409-0367 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 24, 2016 | In Use | |
| 71205-0908-90 | 71205-0908 | LEUCOVORIN CALCIUM | LEUCOVORIN CALCIUM | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 16, 2021 | In Use | |
| 68788-9309-04 | 68788-9309 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 26, 2015 | In Use | |
| 69097-0031-91 | 69097-0031 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 69097-0577-91 | 69097-0577 | nilotinib | NILCEYA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 70518-3612-00 | 70518-3612 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 8, 2023 | In Use | |
| 72493-0106-03 | 72493-0106 | Mitomycin | ZUSDURI | 40.0 mg/each | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravesical | Jul 1, 2025 | In Use |
Found 12250 results — Export these results
Home